CNX-774
CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of [1][2].
Product Specifications
CAS Number
1202759-32-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CNX-774.html
Purity
99.92
Solubility
DMSO : ≥ 45 mg/mL
Smiles
O=C(NC)C1=NC=CC(OC2=CC=C(NC3=NC=C(F)C(NC4=CC=CC(NC(C=C)=O)=C4)=N3)C=C2)=C1
Molecular Formula
C26H22FN7O3
Molecular Weight
499.50
Precautions
H302, H315, H319, H335
References & Citations
[1]Matthew Labenski, et al. In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton's Tyrosine Kinase.|[2]Akintunde Akinleye, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013 Aug 19;6:59.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880752-100 1x 100 µL
Bcl-x (BX006 + 2H12), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042246-100 1x 100 µL
Melanoma Antigen Family A, 4 / MAGEA4 (CPTC-MAGEA4-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details